Hydrocolloid vs microneedle patches: which to private label first?

Hydrocolloid vs microneedle patches: which to private label first?

Short answer: Start with hydrocolloid. It has a lower tooling cost, a lower minimum order, fewer regulatory variables, and it is the format most retail buyers already understand. Microneedle patches are worth adding once you have a working hydrocolloid line and a customer base willing to pay two to three times more for a visibly different mechanism.

Hydrocolloid versus microneedle: unit cost multiple, tooling route, three decision gates Hydrocolloid unit cost is one times; microneedle is two to three times. Hydrocolloid tooling is a die cut at seven to ten days; microneedle needs micro-moulds and a controlled drying step. Add microneedle only when repeat orders exist, the channel carries a premium without discounting, and the claim can be substantiated in the destination market. What each format costs you before it sells Hydrocolloid starts at one unit cost; microneedle starts at two to three, and needs a mould programme instead of a die. Unit cost, relative to hydrocolloid Hydrocolloid 1× Microneedle 2–3× Hydrocolloid tooling — die cut, 7–10 days Microneedle tooling — micro-mould plus a drying step Add microneedle only when all three are true 1 Your hydrocolloid line has repeat orders, not just first orders 2 Your channel carries a premium price without discounting to move stock 3 You have a claim you can substantiate in the destination market Most launches stall on the third gate: settle the claim before artwork. Henso Biotech · both formats in-house · ISO 13485:2016 (NQA 69136) CE Class I · FDA-registered · 28.8 million patches per month

Figure 1 — What each format costs before it sells, and the three tests that justify adding microneedle.

The two products solve different problems

A hydrocolloid patch absorbs fluid from a spot and shields it from picking. It works on a spot that has come to a head. It is passive — the patch does not deliver anything, it removes something and blocks interference.

A microneedle patch carries dissolving micro-structures that penetrate the top layer of skin and release an ingredient — hyaluronic acid, salicylic acid, or a combination. It addresses a spot earlier, before it surfaces, which is the claim behind its higher price.

Both are sold as acne patches. They are not substitutes, and a range that carries only one leaves a gap the other fills.

Side by side

Factor Hydrocolloid Microneedle
Mechanism Absorbs fluid, shields the spot Penetrates and releases an ingredient
Tooling Die cut, 7–10 days Micro-mould plus drying process, longer lead
Unit cost Low Two to three times higher
Regulatory load Class I, self-declaration Higher — ingredient and penetration both matter
Best channel Pharmacy, mass retail, subscription DTC, dermatology-adjacent, premium tier
Repeat purchase driver Price and pack count Perceived result

Why hydrocolloid first

Three practical reasons, in order of how much they cost you if you get them wrong.

Tooling risk. A hydrocolloid patch needs a die. A microneedle patch needs micro-moulds and a controlled drying step. If the design does not sell, you have lost a die cost. If a microneedle geometry does not sell, you have lost a mould programme.

Regulatory surface. A plain hydrocolloid patch is a Class I device. A microneedle patch introduces two variables at once — an active ingredient and a structure that penetrates skin — and the classification question gets harder in every market.

Buyer education. Retail buyers already know what a hydrocolloid patch is. A microneedle patch usually needs a conversation, a sample, and sometimes a clinical reference before a purchase order appears.

When to add microneedle

Add it when three conditions are true, not two:

  • Your hydrocolloid line has repeat orders, not just first orders
  • Your channel can carry a premium price without discounting to move stock
  • You have a claim you can substantiate in your destination market

The third one is where most launches stall. A microneedle patch invites claims about penetration and delivery, and those claims determine the regulatory route. Resolving the claim before designing packaging costs nothing; resolving it after printing does not.

Henso Biotech produces both formats — hydrocolloid and microneedle — in an ISO 13485:2016 certified facility (NQA 69136), CE Class I, FDA-registered. 11,500 m², 8 production lines, 28.8 million patches per month.

Tell us your channel and target retail price, and we will tell you which format fits — including whether the microneedle claim is workable in your market.